摘要
Abstract
Objective:To explore the clinical efficacy and safety of sorafenib combined with adriamycin in the treatment of advanced pancreatic cancer.Methods:A total of 53 patients with advanced pancreatic cancer were divided into single drug group (n=26) and drug combination group (n=27) according to therapeutic protocols.Single drug group was treated with adriamycin 60 mg/m2,ivgtt,once every 21 d,with total dosage of 360 mg/m2.On the base of single drug group,the treatment of drug combination group was added with sorafenib 400 mg,two times 1 d,until tumor deteriorated or patients died.Results:The disease control rate (DCR) was 37.04% in drug combination group,significantly higher than that in the single drug group (11.54%,P<0.05).The median overall survival time (OS) and median progression-free survival time (PFS) were 6.3 months and 3.3 months in the drug combination group,the single drug group were 5.4 months and 2.9 months,the difference between the two groups was statistically significant (P<0.05).Compared with the single drug group,a lower occurrence rate of diarrhea and leucopenia and a higher rate of rash in the drug combination group were found (P<0.05).Conclusion:Sorafenib combined with adriamycin can help to prolong the OS and PFS of patients with advanced pancreatic cancer and tolerate toxic side effects.关键词
索拉菲尼/阿霉素/胰腺癌/总生存期/无进展生存期Key words
Sorafenib/Adriamycin/Pancreatic cancer/Overall survival time/Progression-free survival time分类
医药卫生
